Loading...Loading...BofA Securities analyst Geoff Meacham reiterated the Buy rating on Eli Lilly And Company LLY, with a price forecast of $1,000.An advisory committee to the U.S. Food and Drug Administration (FDA) delivered a favorable verdict on the company’s Alzheimer’s treatment, donanemab, declaring its benefits to surpass the associated risks.The outcome will support regulatory approval of donanemab in patients with mild cognitive impairment/mild dementia, Meacham writes.Moreover, regarding tau strati ...

An FDA committee assessing the safety and effectiveness of Eli Lilly and Company’s (LLY) Alzheimer's disease drug, donanemab, voted 11-0, thus unanimously recommending its approval.The Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) said that data from clinical studies supported the efficacy of donanemab for early symptomatic Alzheimer’s patients. The committee said the studies demonstrated substantial evidence of efficacy and clinically meaningful slowing of disease progression that w ...

LLY has been on an impressive run up the charts in 2024Shares of Eli Lilly And Co (NYSE:LLY) are enjoying a 2.3% surge this morning, last seen trading near $885.10 on the back of news that the Food and Drug Administration (FDA) panel unanimously approved the pharmaceutical company's Alzheimer's drug, donanemab. The FDA cited effectiveness and a beneficial risk/reward outcome. In response, several analysts have donned praise, Jefferies hiking its price target to $994 from $957, saying the FDA backing is a go ...

The world's biggest healthcare company might become even larger.Johnson & Johnson reigned as the largest healthcare company in the world for years. UnitedHealth Group also took a turn at the top. However, the title now belongs to Eli Lilly (LLY 1.77%) -- and it isn't even close.Lilly continues to widen its lead over all other healthcare companies. It just reached yet another all-time high. Is this soaring pharma stock still a buy?Good news galoreYou won't have to look hard to find good news for Lilly that e ...

Key TakeawaysEli Lilly shares rose in extended-hours trading on Monday after a panel of independent advisors unanimously recommended the pharmaceutical giant’s Alzheimer’s drug donanemab, paving the way for its approval later this year.If approved, the drug would join Leqembi, a similar Alzhiemer’s drug manufactured by Biogen and its Japanese partner Eisai, to expand treatment options for the 6 million Americans who live with the disease.Monitor the $795 level during periods of profit taking, an area on the ...

The biotech sector includes companies that develop drugs and diagnostic technologies based on biology. These firms often focus on developing innovative treatments for various medical conditions. Investments in this sector are driven by the potential for significant breakthroughs that can lead to substantial financial returns. However, the sector is known for its high research and development costs and extended periods of testing before potential market release.Investing in biotech stocks offers the potentia ...

Eli Lilly and Company (NYSE:LLY) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 4:00 PM ET Company Participants Patrik Jonsson - Executive Vice President, President of Lilly Diabetes and Obesity and Lilly USA Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, let's get underway here for the Lilly session. One of the most and highly anticipated and we're so appreciative of the entire Lilly team that's here. Lauren Zierki from Investor Relations is always ...

Summary of Eli Lilly and Company Conference Call Company Overview - **Company**: Eli Lilly and Company (NYSE: LLY) - **Event**: Goldman Sachs 45th Annual Global Healthcare Conference - **Date**: June 10, 2024 - **Participants**: Patrik Jonsson (Executive Vice President, President of Lilly Diabetes and Obesity and Lilly USA), Chris Shibutani (Goldman Sachs) Key Points Industry and Market Dynamics - **Obesity and Diabetes Market**: There is an unprecedented demand for obesity treatments, with an estimated 110 million people in the US and 650 million globally suffering from obesity [10][12] - **Manufacturing Capacity**: Eli Lilly has invested over $18 billion in manufacturing since 2020, with plans to increase capacity significantly to meet demand [10][11] Product Launches and Pipeline - **Current Products**: - Mounjaro for Type 2 diabetes has been successfully launched. - Zepbound for chronic weight management was launched six months ago [6][8] - **Pipeline Developments**: - Two promising medicines in Phase 3: Orforglipron (oral GLP-1RA) and Retatrutide (combines glucagon pharmacology) [7][8] - Lepodisiran for Lp(a) has entered Phase 3 [8] Supply Chain and Manufacturing - **Supply Challenges**: Supply has been a limiting factor, but Lilly is expanding manufacturing capacity with new facilities in North Carolina, Indiana, Germany, and Ireland [10][11] - **Production Timelines**: The second site in North Carolina is expected to start production by the end of 2024, with additional sites coming online in 2025 [11] Pricing and Access - **Commercial Access**: As of April 1, 2024, 67% commercial access for Zepbound has been achieved, which is considered high for a new product [16] - **Employer Opt-in**: Approximately 50% of employers are opting in for anti-obesity medications, with expectations for gradual increases [17] - **Medicare Coverage**: The Treat and Reduce Obesity Act (TROA) has bipartisan support, and there are positive movements for Medicare coverage of anti-obesity medications [18][32] Pricing Dynamics - **Net Pricing Trends**: Net pricing is expected to decrease over time as access increases, which is typical for new product launches [19][21] - **Out-of-Pocket Costs**: More patients are paying out-of-pocket for Zepbound compared to Mounjaro, primarily due to access issues [28][29] Patient Adherence and Treatment Duration - **Adherence Expectations**: Patients are expected to stay on treatment longer due to the significant benefits experienced, with a longer duration anticipated compared to other chronic medications [35][36] Future Developments - **Orforglipron**: Expected to democratize access to obesity treatments, with a Phase 3 readout anticipated in 2025 [24][47] - **Retatrutide**: Expected to provide significant weight loss and cardiometabolic benefits, with data readouts in 2026 [51] Additional Mechanisms and Research - **Amylin and GIP Agonists**: Lilly is exploring new mechanisms such as Amylin receptor agonists and GIP agonists, with ongoing studies to assess their efficacy [53][56] - **Alzheimer's Disease**: Lilly is investigating the potential impact of GLP-1s on cognitive decline through improved vascular health, although the primary focus remains on obesity and diabetes [58] Conclusion Eli Lilly is positioned strongly in the obesity and diabetes market with significant investments in manufacturing and a robust pipeline of innovative treatments. The company is addressing supply challenges while navigating pricing dynamics and access issues, with a focus on improving patient outcomes and adherence.

ToplineA Food and Drug Administration advisory panel unanimously voted Monday to recommend Eli Lilly’s Alzheimer’s drug donanemab for approval, according to multiple outlets, sending the pharmaceutical company’s shares up modestly in after-hours trading and making the treatment’s final approval more likely.The panel voted unanimously for the drug. (AP Photo/Michael Conroy, File)Associated Press Key FactsAll of the panel’s 11 members endorsed donanemab—which data from a clinical trial suggests can slow the p ...

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.'s shares climbed in early US trading after its experimental drug for Alzheimer's slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year.The ...